Page last updated: 2024-12-07

perfluorophenanthrene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

perfluorophenanthrene: mixture of isomers of perfluorophenanthrene; MF: C14-F24 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID78972
CHEMBL ID3188494
CHEBI ID39423
SCHEMBL ID145943
MeSH IDM0137697

Synonyms (36)

Synonym
phenanthrene, tetracosafluorotetradecahydro-
zz3t53gwv9 ,
phenanthrene, 1,1,2,2,3,3,4,4,4a,4b,5,5,6,6,7,7,8,8,8a,9,9,10,10,10a-tetracosafluorotetradecahydro-
unii-zz3t53gwv9
perfluoroperhydrophenanthrene
perfluorophenanthrene
CHEBI:39423 ,
tetracosafluorotetradecahydrophenanthrene
306-91-2
phenanthrene,tetracosafluorotetradecahydro-
flutec pp11
1,1,2,2,3,3,4,4,4a,4b,5,5,6,6,7,7,8,8,8a,9,9,10,10,10a-tetracosafluorophenanthrene
cas-306-91-2
dtxsid1047029 ,
NCGC00256219-01
tox21_302291
dtxcid9027029
FT-0676095
perfluoro(perhydrophenanthrene)
AKOS015853419
fiflow 220
flutec pc-11
fiflow 180
perfluorinated tetradecahydrophenanthrene
perfluorotetradecahydrophenanthrene
perfluoroperhydrophenanthrene [inci]
flutec pp 11
SCHEMBL145943
fc 5311
CHEMBL3188494
mfcd00042596
flutec pp11 for electronic applications
perfluoroperhydrophenanthrene, selectophore(tm)
J-018059
CS-0207499
Q27119859

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
radioopaque mediumA substance having the property of absorbing, and therefore being opaque to, electromagnetic radiation, particularly X-rays.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
fluorocarbonCompounds consisting wholly of fluorine and carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency22.30400.000714.592883.7951AID1259369
estrogen nuclear receptor alphaHomo sapiens (human)Potency49.93230.000229.305416,493.5996AID743079
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (40)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.50)18.7374
1990's32 (80.00)18.2507
2000's4 (10.00)29.6817
2010's1 (2.50)24.3611
2020's2 (5.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.24 (24.57)
Research Supply Index4.11 (2.92)
Research Growth Index6.35 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (17.65%)5.53%
Reviews0 (0.00%)6.00%
Case Studies12 (23.53%)4.05%
Observational0 (0.00%)0.25%
Other30 (58.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]